[EN] PREPARATION METHOD FOR TYROSINE KINASE INHIBITOR AND INTERMEDIATE THEREOF<br/>[FR] PROCÉDÉ DE PRÉPARATION D'INHIBITEUR DE TYROSINE KINASE ET D'INTERMÉDIAIRE DE CELUI-CI<br/>[ZH] 一种酪氨酸激酶抑制剂及其中间体的制备方法
Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof
申请人:Lu Qinghong
公开号:US20120289545A1
公开(公告)日:2012-11-15
The present invention relates to maleate salt forms of (E)-N-4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF
申请人:Wyeth LLC
公开号:EP3088398A1
公开(公告)日:2016-11-02
The present invention relates to isolated crystalline forms of (E)-N-4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide maleate and to pharmaceutical compositions comprising the same.
MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF
申请人:Wyeth LLC
公开号:US20130281488A1
公开(公告)日:2013-10-24
The present invention relates to maleate salt forms of (E)-N-4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.
MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF
申请人:Wyeth LLC
公开号:US20160068511A1
公开(公告)日:2016-03-10
The present invention relates to maleate salt forms of (E)-N-4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.